Solid Biosciences Inc. (SLDB)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB). The investigation concerns whether Solid Biosciences and certain of its officers and/or directors have violated federal securities laws.
On November 12, 2019, Solid Biosciences disclosed that the U.S. Food and Drug Administration (“FDA”) had placed the Company’s Ignite DMD Phase I/II clinical trial evaluating gene therapy candidate SGT-001 in Duchene muscular dystrophy on clinical hold as the result of a serious adverse event related to the study drug. On this news, Solid Biosciences’ stock price fell $8.18 per share, or 74.36%, to close at $2.82 per share on November 12, 2019. Then, on July 27, 2020, Solid Biosciences announced that the FDA had notified the Company on July 24, 2020 that the agency was maintaining the clinical hold and requested “further manufacturing information, updated safety and efficacy data for all patients dosed, and providing direction on total viral load to be administered per patient.” On this news, Solid Biosciences’ stock price fell $0.30 per share, or 10.53%, to close at $2.55 per share on July 27, 2020.
If you are aware of any facts relating to this investigation, or purchased Solid Biosciences shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.